

Amendments to the Claims:

This listing of claims will replace all previous versions and listings, of claims in the application:

Listing of Claims:

Claims 1- 38. (Canceled)

Claim 39. (New) A method of diagnosing a cancer nonspecific to an organ comprising the steps of:

applying a cancer cell specific HLA-F antigen to a body fluid of a subject; and

reacting the cancer cell specific HLA-F antigen with an anti HLA-F antibody in the body fluid of the subject; and

qualitatively or quantitatively detecting an immune complex of the cancer cell specific HLA-F antigen and the cancer cell specific anti HLA-F antibody; and

diagnosing the subject has a cancer nonspecific to an organ.

Claim 40. (New) The method of claim 39, wherein the body fluid is blood.

Claim 41. (New) The method of claim 39, wherein the qualitatively or quantitatively detecting immune complex comprising the steps of:

reacting a labeled secondary antibody to the immune complex; and

detecting the labeled secondary antibody which binds to the immune complex.

Claim 42. (New) The method of claim 41, wherein the labeled secondary antibody is selected from the group consisting of an anti-human IgG rabbit antibody, an anti-human IgG mouse antibody, and an anti-human IgG goat antibody.

Claim 43. (New) The method of claim 39, wherein the cancer nonspecific

to an organ is selected from the group consisting of liver cancer, stomach cancer, uterine cancer, breast cancer, pancreatic cancer, and ovarian cancer.

Claim 44. (New) The method of claim 39, wherein the cancer nonspecific to an organ is selected from the group consisting of liver cancer and stomach cancer.

Claim 45. (New) The method of claim 39, wherein the cancer nonspecific to an organ is selected from the group consisting of liver cancer and uterine cancer.

Claim 46. (New) The method of claim 39, wherein the cancer nonspecific to an organ is selected from the group consisting of uterine cancer and stomach cancer.

Claim 47. (New) The method of claim 39, wherein the cancer cell specific HLA-F antigen comprises at least a part of the amino acid sequence in SEQ ID No. 6 in the Sequence Listing.

Claim 48. (New) The method of claim 39, wherein the cancer cell specific HLA-F antigen comprises at least a part of the amino acid sequence in SEQ ID No. 5 in the Sequence Listing.

Claim 49. (New) The method of claim 39, wherein the cancer cell specific HLA-F antigen is obtained by expressing a DNA as its entirety or part of it described in sequence selected from the group consisting of SEQ ID Nos. 1, 2, and 3.

Claim 50. (New) A method of diagnosing a cancer nonspecific to an organ comprising the steps of:

applying a known amount of cancer cell specific antigen and an labeled anti HLA-F antibody to a body fluid of a subject; and

competitively reacting the labeled anti HLA-F antibody and the anti-HLA-F antibody in the body fluid of the subject; and

detecting an immune complex of the cancer cell specific HLA-F antigen and the labeled anti HLA-F antibody; and

diagnosing a subject has a cancer nonspecific to an organ.

Claim 51. (New) The method of claim 50, wherein the body fluid is blood.

Claim 52. (New) the method of claim 50, wherein a cancer nonspecific to an organ is selected from the group consisting of liver cancer, stomach cancer, uterine cancer, breast cancer, pancreatic cancer, and ovarian cancer.

Claim 53. (New) The method of claim 50, wherein a cancer nonspecific to an organ is selected from the group consisting of liver cancer and stomach cancer.

Claim 54. (New) The method of claim 50, wherein a cancer nonspecific to an organ is selected from the group consisting of liver cancer and uterine cancer.

Claim 55. (New) The method of claim 50, wherein a cancer nonspecific to an organ is selected from the group consisting of uterine cancer and stomach cancer.

Claim 56. (New) The method of claim 50, wherein a cancer cell specific HLA-F antigen comprises at least a part of the amino acid sequence in SEQ ID No. 6 in the Sequence Listing.

Claim 57. (New) The method of claim 50, wherein a cancer cell specific HLA-F antigen comprises at least a part of the amino acid sequence in SEQ ID No. 5 in the Sequence Listing.

Claim 58. (New) The method of claim 50, wherein a cancer cell specific HLA-F antigen is obtained by expressing a DNA as its entirely or part of its described in sequence selected from the group consisting of SEQ ID Nos. 1, 2, and 3.

Claim 59. (New) A method of diagnosing a cancer nonspecific to an organ comprising the

step of detecting an HLA-F antibody in a body fluid of a subject by using a cancer cell-specific HLA-F antigen as its entirety or part of it.